Alexion’s Bedrosian Named Chief Medical Officer of Ultragenyx

Xconomy San Francisco — 

Rare disease drug developer Ultragenyx Pharmaceutical (NASDAQ: RARE) has named Camille Bedrosian executive vice president and chief medical officer. Before joining the Novato, CA-based company, Bedrosian was senior vice president and chief medical officer of Alexion Pharmaceuticals (NASDAQ: ALXN) in New Haven, CT. Ultragenyx added gene therapy to its drug pipeline last fall through its acquisition of Cambridge, MA-based Dimension Therapeutics.